Late-stageMS opportunity Mapi Pharma is in the final stage of Phase III with GA Depot for relapsing MS and has an active exclusive license with Mylan/Viatris for commercializing GA Depot. This presents a near-term opportunity to engage in co-promotion, regional partnerships, or expansion into additional markets where GA Depot could be introduced to complement existing MS therapies.

GI and CNS pipeline Beyond MS, Mapi is developing long-acting depots for GLP-1s and neurodegenerative targets, plus a potential anti-psychotic depot. This diversified depot platform indicates cross-therapy partnering possibilities across diabetes, obesity, Parkinson’s, and psychiatric indications, enabling multi-asset collaboration discussions with large pharma.

Strategic partnerships Mapi is actively seeking strategic partners for its depot technologies and for late-stage products. The existing license with Mylan/Viatris demonstrates openness to collaboration, suggesting opportunities for co-development, manufacturing partnerships, or regional distribution deals to accelerate market access.

Manufacturing footprint With API production in Neot-Hovav and a sizeable injectable Fill & Finish facility in Jerusalem, Mapi has significant in-house capabilities. This presents a sales angle for integrated supply agreements, fill-finish capacity expansion, and potential manufacturing services for partner programs seeking depot formulations.

Clinical momentum Mapi has ongoing Phase II/III activity and presentations at major conferences (AAN, ASCO, ADA, ACTRIMS). This evidence generation cadence signals opportunities to align BD efforts with their trial milestones, enabling partner discussions around data-driven commercialization strategies and early access arrangements.